The EpiCast Report that predicts how many people epilepsy will affect by the year 2022 has been released. This report helps drug companies prepare for the expanding market.
See the press release below. The full report is available for purchase here for merely $6,995 (Obviously we don’t recommend that you purchase this unless you work for a major pharmaceutical company): http://www.researchandmarkets.com/research/ncxgls/epicast_report
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/ncxgls/epicast_report) has announced the addition of GlobalData’s new report “EpiCast Report: Epilepsy – Epidemiology Forecast to 2022” to their offering.
“EpiCast Report: Epilepsy – Epidemiology Forecast to 2022”
EpiCast Report: Epilepsy – Epidemiology Forecast to 2022
Epilepsy affects 50 million people worldwide each year and is one of the most common neurological conditions in the world (WHO, 2005). Epilepsy is defined as a collection of brain dysfunction disorders characterized by recurrent and unpredictable seizures. The prevalence of epilepsy varies among countries due to a mosaic of economic, political, and social differences. GlobalData epidemiologists expect that the number of active and lifetime prevalent cases of epilepsy will increase during the forecast period (2012-2022) in the nine markets covered. In 2012, we estimated that there was a total of 17,542,651 active prevalent cases of epilepsy in the nine markets, and GlobalData epidemiologists forecast that by 2022, the number of active prevalent cases will grow to 18,565,967. A major strength of this analysis is that the forecast methodology was consistent across the nine markets to allow for a meaningful comparison of the patient populations in each country.
– The Epilepsy EpiCast Report provide an overview of risk factors and global trends for epilepsy.
– Data is provided for the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan) along with emerging marketsIndia and China.
– It includes a 10-year epidemiological forecast of active and lifetime prevalent cases of epilepsy segmented by gender, age, treatment gap, and seizure type (generalized, partial, and unknown).
Key Topics Covered:
1 Tables & Figures
3.1 Risk Factors and Comorbidities
3.1.1 Risk factors in newborns often include brain malformations and lack of oxygen
3.1.2 Genetic factors and head trauma are risk factors in adults and children
3.1.3 Common seizure triggers include lack of sleep, stress, and photo-sensitivity
3.1.4 Epilepsy comorbidities in adults and children include pain disorders
3.1.5 Anxiety and depression are major epilepsy comorbidities
3.1.6 Epilepsy with a known cause can be prevented by the avoidance of head injuries
3.2 Global Trends
3.3 Forecast Methodology
3.4 Epidemiologic Forecast
3.4.1 Total Active Prevalent Cases of Epilepsy
3.4.2 Total Lifetime Prevalent Cases of Epilepsy
3.4.3 Age-Specific Total Active Prevalent Cases of Epilepsy
3.4.4 Gender-Specific Total Active Prevalent Cases of Epilepsy
3.4.5 Seizure-Specific Total Active Prevalent Cases of Epilepsy
3.5.1 Conclusion on Epidemiological Trends
3.5.2 Limitations of the Analysis
3.5.3 Strengths of the Analysis
For more information visit http://www.researchandmarkets.com/research/ncxgls/epicast_report